Trastuzumab conjugate (BioIntegrator)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameTrastuzumab conjugate (BioIntegrator)
Drug Alias NameBI-CON-02
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsMetastatic breast cancer
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryRussian Federation
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBiointegrator Llc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBiointegrator Llc
Active IndicationsN/A
Inactive IndicationsMetastatic breast cancer

Other Information

ATC CodeN/A
Related LinksN/A